Catalyst Pharmaceuticals Inc. (CPRX)
NASDAQ: CPRX · Pharmaceutical Preparations · Coral Gables, FL
Our rating: Positive
Positive reaffirmed at $31.38, moderate conviction, June 18, 2026.
Breaks if: The positive call would be disproved if reported revenue growth falls below 10% on a trailing twelve-month basis at any results print through June 2027, or if net margin drops below 28% in two consecutive reported quarters — either would suggest the commercial franchise is decelerating faster than today's multiple assumes.
Key figures
| Market value | $3.9B |
|---|---|
| Revenue, last 12 months | $597M |
| Net income, last 12 months | $221M |
| Free cash flow, last 12 months | $208M |
| Price to earnings | 17.4× |
| Free cash flow yield | 5.4% |
| Dividend yield | 0.0% |
| Operating margin | 44.8% |
| Return on equity | 24.5% |
| Beta to the S&P 500 | 0.85 |
| Volatility, annualized | 36.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| March 31, 2026 | $149M | 5.6% | $0.50 | $60M |
| December 31, 2025 | $153M | 7.6% | $0.41 | $45M |
| September 30, 2025 | $148M | 15.3% | $0.42 | $32M |
| June 30, 2025 | $147M | 19.4% | $0.41 | $71M |
| March 31, 2025 | $141M | 43.6% | $0.45 | $60M |
| December 31, 2024 | $142M | 28.3% | $0.44 | $71M |
| September 30, 2024 | $129M | 25.3% | $0.35 | $73M |
| June 30, 2024 | $123M | 23.2% | $0.33 | $64M |
6 ledger entries and 54 corporate events on record. Share price as of July 16, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.